Combined Anti-Angiogenic Therapy Targeting PDGF and VEGF Receptors Lowers the Interstitial Fluid Pressure in a Murine Experimental Carcinoma
暂无分享,去创建一个
C. Heldin | M. Burmakin | C. Hellberg | R. Reed | Y. Hasumi | K. Rubin | L. Stuhr | A. Åhgren | Agnieszka Kłosowska-Wardęga | I. Moen | A. Ahgrén
[1] E. Buchdunger,et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. , 2008, European journal of pharmacology.
[2] Christopher Korch,et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. , 2008, The Journal of clinical endocrinology and metabolism.
[3] C. Heldin,et al. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling , 2007, International journal of cancer.
[4] A. Oldberg,et al. Collagen-binding proteoglycan fibromodulin can determine stroma matrix structure and fluid balance in experimental carcinoma , 2007, Proceedings of the National Academy of Sciences.
[5] M Beth McCarville,et al. Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy , 2007, Clinical Cancer Research.
[6] K. Alitalo,et al. Molecular regulation of angiogenesis and lymphangiogenesis , 2007, Nature Reviews Molecular Cell Biology.
[7] R. Reed,et al. Inhibition of carcinoma cell‐derived VEGF reduces inflammatory characteristics in xenograft carcinoma , 2006, International journal of cancer.
[8] T. Nedrebø,et al. Platelet-Derived Growth Factor BB–Mediated Normalization of Dermal Interstitial Fluid Pressure After Mast Cell Degranulation Depends on &bgr;3 but Not &bgr;1 Integrins , 2006 .
[9] Kristian Pietras,et al. High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.
[10] Ricky T. Tong,et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.
[11] Michael Stumm,et al. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] L. Johansson,et al. Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[13] R. Groszmann,et al. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. , 2003, Cancer cell.
[14] Tobias Sjöblom,et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. , 2002, Cancer research.
[15] Alex Matter,et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.
[16] Rakesh K Jain,et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. , 2002, The American journal of pathology.
[17] C. Heldin,et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. , 2001, Cancer research.
[18] M Ancukiewicz,et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. , 2000, Cancer research.
[19] R. Reed,et al. Lowering of tumoral interstitial fluid pressure by prostaglandin E1 is paralleled by an increased uptake of 51Cr‐EDTA , 2000, International journal of cancer.
[20] J. Mestan,et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.
[21] C. Heldin,et al. Mechanism of action and in vivo role of platelet-derived growth factor. , 1999, Physiological reviews.
[22] R. Reed,et al. A novel physiological function for platelet‐derived growth factor‐BB in rat dermis. , 1996, The Journal of physiology.
[23] K. Ain,et al. Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in vitro. , 1994, The Journal of clinical endocrinology and metabolism.
[24] P. Workman,et al. UKCCCR guidelines for the welfare of animals in experimental neoplasia. , 1988, British Journal of Cancer.
[25] J. Levick. Flow through interstitium and other fibrous matrices. , 1987, Quarterly journal of experimental physiology.
[26] Rakesh K. Jain,et al. Taming vessels to treat cancer. , 2008, Scientific American.
[27] T. Nedrebø,et al. Platelet-derived growth factor BB-mediated normalization of dermal interstitial fluid pressure after mast cell degranulation depends on beta3 but not beta1 integrins. , 2006, Circulation research.
[28] R K Jain,et al. Haemodynamic and transport barriers to the treatment of solid tumours. , 1991, International journal of radiation biology.